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Abstract
BackgroundandAims:Although several studies have suggested opium as a risk factor for cancers of the esophagus, stomach,
larynx, lung, and bladder, no previous study has examined the association of opium with pancreatic cancer. We aimed to study the
association between opium use and risk of pancreatic cancer in Iran, using a case-control design. We also studied the association of
cigarette smoking and alcohol consumption with pancreatic cancer, for which little information was available from this population.
Methods:Cases and controls were selected from patients who were referred to 4 endoscopic ultrasound centers in Tehran, Iran.
We recruited 316 histopathologically (all adenocarcinoma) and 41 clinically diagnosed incident cases of pancreatic cancer, as well as
328 controls from those with a normal pancreas in enodosonography from January 2011 to January 2015. We used logistic
regression models to calculate odds ratios (ORs) and 95% conﬁdence intervals (CIs).
Results: After adjustment for potential confounders, opium use (OR 1.91; 95% CI 1.06–3.43) and alcohol consumption (OR 4.16;
95% CI 1.86–9.31) were signiﬁcantly associated with an increased risk of pancreatic cancer. We did not ﬁnd an association between
ever tobacco smoking and pancreatic cancer risk (OR 0.93; 95% CI 0.62–1.39).
Conclusion: In our study, opium use and alcohol consumption were associated with an increased risk of pancreatic cancer,
whereas cigarette smoking was not.
Abbreviations: CIs = conﬁdence intervals, CT = computed tomography, EUS = endoscopic ultrasonography, FNA = ﬁne needle
aspiration, H&E = hematoxylin and eosin, ORs = odds ratios, UNODC = United Nations Ofﬁce of Drugs and Crime.
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11. Introduction
According to the United Nations Ofﬁce of Drugs and Crime
(UNODC), an estimated 16.5 million people use opium or its
derivatives illicitly.[1] The acute effects of opium use—such as its
analgesic and soporiﬁc effects—have been known for millennia.
However, its long-term effects on health, such as its potential
carcinogenic effects, have been studied only since the 1970s,
mostly over the past decade.[2] Several case-control and cohort
studies have suggested that opium use may increase the risk of
cancers of the esophagus,[3–6] stomach,[4,7–9] larynx,[10,11]
lung,[12–14], and bladder.[15–21] These epidemiologic ﬁndings
are supported by laboratory studies showing that, after metabolic
activation, opium dross has mutagenic activity in Salmonella
typhimurium strains TA98 and TA100;[22] causes frameshift
mutations in S typhimurium strains TA1538 and TA98;[23] and
induces sister chromatid exchanges.[24] These effects are mostly
attributed to nitrogen-containing heterocyclic compound derived
from pyrolysis of morphine.[25] To our knowledge, no previous
study has examined its association with pancreatic cancer.
Cigarette smoking is a known cause of pancreatic cancer.
Several meta-analyses have shown increased risk of pancreatic
cancer as a result of cigarette smoking, mostly with odds ratios
(OR) of 1.5 to 2.0, depending on the duration and intensity of
smoking.[26–28] However, the association of smoking with
various cancers in Iran has often been much less strong than
what is seen in Western countries.[5,9,14,29] Alcohol consumption
may be another risk factor; whereas some studies have shown no
increased risk, others have suggested that alcohol consumption
Shakeri et al. Medicine (2016) 95:28 Medicinemay be associated with higher risk of pancreatic cancer. A recent
meta-analysis indicated that heavy, but not low consumption of
alcohol, was associated with an increased risk of pancreatic
cancer.[30]
We aimed to study the association between opium use and risk
of pancreatic cancer in Iran, using a case-control design. We have
also investigated the association between cigarette smoking and
alcohol consumption with risk of pancreatic cancer in our study
population.2. Methods
2.1. Overall design and study procedures
This case-control study was approved by the Institutional Review
Board of Digestive Disease Research Center, Tehran University of
Medical Sciences (IRB number: IRB00001641, Federal wide
Assurance number: FWA00015916). Study participants were
recruited from patients referred for endoscopic ultrasonography
(EUS) to 3 tertiary referral hospitals (Shariati, Firoozgar, and
Atieh Hospitals) or a specialty clinic (Masoud Clinic) in Tehran,
Iran, from January 2011 to January 2015. Patients were visited
and assessed clinically by an endosonographist for one of the
following reasons: suspicion for a mass or cyst in the pancreas or
bile ducts; assessment of submucosal lesions found during
esophago-gastro-duodenal endoscopy; or to rule out bile duct
stones. If, based on history and clinical assessment, the endo-
sonogrphist had a suspicion of pancreatic mass, the patient was
asked to participate in the study. This invitation was made based
on suspicion only and before endosonography was done. After
obtaining informed consent, the patient was referred to a trained
general practitioner for interview and biological sample collec-
tion. Potential study participants were administered a detailed
questionnaire; provided blood, saliva, and urine samples; and
underwent EUS. The tissue samples obtained during EUS were
read by expert pathologists. Cases (those with pancreatic
adenocarcinoma) and controls (those without pancreatic adeno-
carcinoma) were selected based on the results of history of their
signs and symptoms, clinical exams, EUS, histopathology, and
other information obtained during data collections.2.2. Questionnaire data
Trained general practitioners administered a structured ques-
tionnaire with 113 questions to each study participant. The
questionnaire was completed before endosonography was done
for 2 reasons: (1) the physicians and the patients were unaware of
the ﬁnal diagnosis; therefore, the chance of interviewer or
responder bias was reduced; and (2) the patients could respond to
questions more accurately before receiving sedation for endo-
sonography. We collected data on demographics; anthropomet-
ric indices; socioeconomic status indicators; signs and symptoms
of the current disease; occupational history and exposure to
certain physical and chemical agents; medical and drug history;
family history of cancer; history of alcohol, tobacco, or opium
use; history of tea and coffee consumption; pregnancy and
menstrual data (only for women); and dietary habits and cooking
methods. This questionnaire was tested for and showed excellent
validity and reliability.[31]
Questions on opium use included being an ever user (having
used at least weekly for a period of 6 months or more), age of
initiation of use, duration of use (in years), frequency of use (per
week), and typical amount of use (in a local unit called nokhod,2roughly 0.2g). Questions also included routes of use (ingestion,
inhalation, and injection) and types of opium locally used (teriak,
shireh, sukhteh, and heroin). Teriak is the air-dried sticky paste of
raw opium. Sukhteh is the dry, black residue of smoked teriak,
which sticks to the opium pipe. It can be scraped from the opium
pipe and ingested. Shireh is reﬁned opium product often made by
boiling a combination of raw opium and sukhteh in hot water
and passing the solution through ﬁlters several times.2.3. Biological sample collection and other assessments
The general practitioners also measured height and weight of the
patients and collected samples of blood, saliva, and urine using
predeﬁned protocols. All biological samples were transferred to
–20 oC freezers within 15 minutes of collection, and then to –70
oC freezers within 48hours. The practitioners also collected a
copy of all previous patient records, including medical charts,
laboratory data, and diagnostic imaging in a ﬁle.
EUS: All of the above patients were offered EUS, and if they
had mass or cystic lesions, underwent ﬁne needle aspiration
(FNA). The only exception was those who were highly suspicious
for insulinoma based on laboratory ﬁndings. One of four expert
endosonographists, each with >5 years of experience, conducted
the exams. The endosonographists attempted at least 3 needle
passes to obtain adequate tissue. If adequate tissue was not
obtained using this method, histological sampling was done using
a second ﬁne needle aspiration, or rarely under the computed
tomography (CT) scanning. Pentax EUS machines were used in
Shariati and Atieh hospitals and Masoud Clinic, whereas a
Fujinon machine was used in Firoozgar Hospital.2.4. Histopathological exam
An experienced pathologist evaluated all samples collected using
EUS or other methods described above. If a deﬁnitive diagnosis of
ductal adenocarcinoma could not be made using hematoxylin/
eosin (H&E) staining, the samples were evaluated using an
immunohistochemistry panel to differentiate ductal adenocarci-
noma from neuroendocrine tumors, pseudopapillary tumors, or
lymphoma.
Cases: For this study, pancreatic cancer cases deﬁned as those
who either received a histopathological diagnosis of pancreatic
adenocarcinoma or were clinically diagnosed as pancreatic
cancer.2.5. Controls
Controls were those who had all of the following qualiﬁcations:
normal pancreas in the EUS exam; age 40 years or older; a ﬁnal
diagnosis of either asymptomatic small (<10mm) submucosal
lesion in the esophagus or stomach, or a gallbladder or common
bile duct stones without cholangitis; no history or current
diagnosis of liver failure or renal failure; no history of cancer; no
adherence to special diets; no diagnosis of opium-induced
common bile duct dilatation or sphincter of Oddi dysfunction;
and no development of pancreatic disease or any cancers 1 year
after the initial visit. There is substantial literature [32–36] showing
that opium could cause common bile duct dilatation or sphincter
of Oddi dysfunction. However, such diagnosis was made only
after careful investigation and ruling out all other causes. This last
criterion (no cancer after 1 year of follow up) was applied to
make sure that there no subclinical lesions or was no
misdiagnosis in the initial visit. One year after the initial visit,
Table 1
Demographic characteristics of pancreatic cancer cases and
controls.
Cases Controls
N 357 328
Age, y, mean, SD 64.6 (11.5) 64.7 (11.7)
Gender, N (%)
Female 141 (39.5) 179 (54.6)
Male 216 (60.5) 149 (45.4)
Ethnicity, N (%)
Fars 174 (48.7) 140 (42.7)
Turk 111 (31.1) 123 (37.5)
Kord 27 (7.6) 34 (10.4)
Lor 23 (6.4) 27 (8.2)
Others 22 (6.2) 4 (1.2)
Residence, N (%)
Rural 70 (19.6) 41 (12.5)
Urban 287 (80.4) 287 (87.5)
Marital status N (%)
Married 290 (81.2) 246 (75.0)
Widowed 61 (17.1) 75 (22.9)
Single or divorced 6 (1.7) 7 (2.1)
Education, N (%)
Illiterate 147 (41.2) 136 (41.5)
5 y 73 (20.4) 75 (22.9)
6–8 y 40 (11.2) 31 (9.4)
9–12 y 52 (14.6) 49 (14.9)
University level 45 (12.6) 37 (11.3)
SD= standard deviation.
Table 2
Opium use in pancreatic cancer cases and controls.
Cases Controls
Unadjusted
OR (95%CI)
for PC
Adjusted
∗
OR (95%CI)
for PC
N 357 328
Opium use
Never 300 (84.0) 307 (93.6) Reference Reference
Ever 57 (16.0) 21 (6.4) 2.77 (1.64–4.69) 1.91 (1.06–3.43)
Opium use†
Never 302 (84.6) 307 (93.6) Reference Reference
Ever 55 (15.4) 21 (6.4) 2.66 (1.57–4.51) 1.82 (1.01–3.29)
Unit per day‡
Never used 305 (85.4) 307 (93.6) Reference Reference
Medianx
(2 nokhods
per day)
41 (11.5) 15 (4.6) 2.75 (1.49–5.07) 1.89 (0.97–3.69)
>Median 11 (3.1) 6 (1.8) 1.84 (0.67–5.05) 1.19 (0.41–3.51)
Duration
Never used 305 (85.4) 307 (93.6) Reference Reference
Median (20 y) 22 (6.2) 11 (3.4) 2.01 (0.95–4.22) 1.61 (0.72–3.52)
>Median 30 (8.4) 10 (3.1) 3.01 (1.45–6.28) 1.79 (0.81–3.97)
Cumulative usejj
Never used 305 (85.4) 307 (93.6) Reference Reference
Median
(34 nohkod-years)
26 (7.3) 11 (3.4) 2.37 (1.15–4.91) 1.85 (0.85–4.01)
>Median 26 (7.3) 10 (3.1) 2.61 (1.24–5.51) 1.52 (0.67–3.43)
Age started
Never used 305 (85.4) 307 (93.6) Reference Reference
>Median 9 (2.5) 9 (2.7) 1.01 (0.39–2.57) 0.82 (0.31–2.21)
Median (40 y) 43 (12.0) 12 (3.7) 3.61 (1.86–6.97) 2.36 (1.14–4.87)
CI=conﬁdence interval, OR= odds ratio, PC=pancreatic cancer.
∗
Adjusted for age, sex, residence, alcohol use, and ever use of any type of tobacco.
† After reclassifying opium users who started opium use within 1 y before cancer diagnoses.
‡ Each unit is 1 “nokhod,” which is approximately equal to 0.2 g.
xWe used the median in control subjects as the dividing cut point.
jj Cumulative use was calculated by multiplying intensity of use (nokhods per day) by duration of use
(in years).
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patient or their relative to ensure that no pancreatic disease or
other disease had developed during that year. Patients who did
not match one or more of the above-mentioned criteria (e.g.,
those with submucosal lesions of >10mm) were excluded from
the list of controls.2.6. Statistical analysis
Statistical analyses were conducted with Stata statistical
software, version 11 (STATA Corp, College Station, TX).
Frequencies and percentages were calculated for categorical
variables, and means and standard deviations were calculated for
continuous variables. We used logistic regression models to
calculate odds ratios (OR) and 95% conﬁdence intervals (95%
CI) for the association of the main exposures (opium use,
cigarette smoking, and alcohol consumption) with case status. In
addition to unadjusted results, we present the ORs and 95% CIs
adjusted for potential confounders, including age, sex, place of
residence (urban or rural), and mutual consumption of opium
use, smoking, and alcohol consumption. Education and marital
status were not associated with pancreatic cancer risk and
therefore were not included in the ﬁnal models.
In addition to analyzing the main exposures as dichotomous
variables (ever vs never), we analyzed and show the association
for average amount of use, duration of use, and cumulative use
(deﬁned as duration of use, in days, multiplied by daily amount of
use). We show OR (95% CI) for the association of opium use by
routes of administration.
A main concern for the association of opium and case status is
reverse causality, as patients may use opium to alleviate pain. To
address reverse causality, we also dropped from analysis any
opium use during 1, 2, and 3 years prior to diagnosis.33. Results
Of the initial pool of 1726 patients who underwent EUS from
January 2011 to January 2015, a total of 357 cases of pancreatic
cancer and 328 controls were enrolled in this study.
Table 1 compares demographic characteristics and other
potential confounders of interest for cases and controls. The
mean (standard deviation) age for controls and cases were 64.6
(11.5) versus 64.7 (11.7) years, respectively; 45.4% of controls
and 60.5% of the cases were males. Controls and cases were
substantially different in terms of place of residence (urban vs
rural) but not for ethnicity, marital status, or education.
Table 2 shows adjusted and unadjusted results for the
association between opium use and pancreatic cancer. Overall,
57 cases (16.0%) compared to only 21 controls (6.4%) had ever
used opium, resulting in an unadjusted OR (95% CI) of 2.77
(1.64–4.69) and an adjusted OR (95% CI) of 1.91 (1.06–3.43).
To ensure that opium use was not started because of cancer-
related pain, in a sensitivity analysis we reclassiﬁed the cancer
cases who started opium use within 1, 2, and 3 years prior to
diagnosis as nonusers. This reclassiﬁcation led to the exclusion of
2, 3, and 5 exposed cases, respectively, and no exposed controls.
The adjusted OR (95% CI) was of 1.82 (1.01–3.29) for
reclassifying the results for 1 year prior to diagnosis, which
was statistically signiﬁcant. After reclassifying the results for 2 or
3 years prior to diagnosis, the adjusted OR (95% CI) were 1.76
Table 3
Cigarette in pancreatic cancer cases and controls.
Cases Controls Unadjusted OR (95%CI) for PC Adjusted
∗
OR (95%CI) for PC
N 357 328
Cigarette smoking, N (%)
Never used 234 (65.5) 244 (74.4) Reference Reference
Ever used 123 (34.5) 84 (25.6) 1.52 (1.09–2.12) 0.93 (0.62–1.39)
Cigarette smoking, N (%)
Never used 234 (65.5) 244 (74.4) Reference Reference
Ex-smoker 68 (19.1) 51 (15.6) 1.39 (0.92–2.08) 0.93 (0.59–1.47)
Current-smoker 55 (15.4) 33 (10.1) 1.73 (1.08–2.77) 0.93 (0.53–1.62)
Average per day
Never used 234 (65.5) 244 (74.4) Reference Reference
Median†
(10.5 cigarettes/day) 43 (12.0) 42 (12.8) 1.06 (0.67–1.69) 0.75 (0.45–1.25)
>Median 80 (22.4) 42 (12.8) 1.98 (1.31–3.01) 1.13 (0.69–1.83)
Duration
Never used 234 (65.5) 244 (74.4) Reference Reference
Median (30 y) 48 (13.5) 46 (14.0) 1.08 (0.69–1.69) 0.71 (0.43–1.18)
>Median 75 (21.0) 38 (11.6) 2.05 (1.33–3.16) 1.21 (0.73–1.99)
Pack year
Never used 234 (65.5) 244 (74.4) Reference Reference
Median (13.5 pack-years) 39 (10.9) 44 (13.4) 0.92 (0.57–1.47) 0.66 (0.39–1.11)
>Median 84 (23.5) 40 (12.2) 2.18 (1.44–3.32) 1.25 (0.77–2.05)
Age started
Never used 234 (65.5) 244 (74.4) Reference Reference
>Median 40 (11.2) 36 (11.0) 1.15 (0.71–1.88) 0.77 (0.45–1.33)
Median (22 y) 83 (23.3) 48 (14.6) 1.81 (1.21–2.68) 1.06 (0.66–1.7)
CI= conﬁdence interval, OR=odds ratio, PC=pancreatic cancer.
∗
Adjusted for age, sex, residence, alcohol, and opium use.
†We used the median in control subjects as the dividing cut point.
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adjusted ORs were not signiﬁcant, the ORs were still
substantially above 1 and very close to the original results.
Further analyses (Table 2) did not indicate a dose–response
relationship between opium use and pancreatic cancer. No higher
risk was associated higher average intensity of dose, longer
duration of use, or cumulative use.
Table 3 demonstrates the results for association of cigarette
smoking with pancreatic cancer. Whereas the unadjusted results
show a statistically signiﬁcant association (OR 1.52; 95% CI
1.09–2.12), the adjusted results show almost no association (OR
0.93; 95%CI 0.62–1.39). Further analyses indicated no evidence
for a dose–response association. The main confounding factors
were sex, opium use, and alcohol consumption.
The association between alcohol consumption and pancreatic
cancer is shown in Table 4. Among cases, 39 (10.9%) had
consumed alcohol, compared to 8 controls (2.4%), resulting in an
unadjusted OR (95%) CI of 5.33 (2.46–11.54) and an adjusted
OR (95%CI) of 4.16 (1.86–9.3). Longer duration of use, but not
higher cumulative use, was associated with a higher risk.
Finally, we have illustrated the relationship of pancreatic
cancer and alcohol, opium, and tobacco use with weighted
markers, in supplementary Figure 1, http://links.lww.com/MD/
B115.4. Discussion
In our study population, opium use and alcohol consumption,
but not cigarette smoking, were associated with an increased risk
of pancreatic cancer.
Whereas this is the ﬁrst study of opium in relation to pancreatic
cancer, the results support the currently existing literature4indicating that opium use may be carcinogenic. Several
methodologic problems need to be considered before making a
causal conclusion. The association between opium use and higher
risk of cancer may be confounded by other risk factors, such as
age, sex, tobacco use, and alcohol use. Opium users are more
likely to be older men who also smoke cigarettes.[37] However,
adjustment for these potential confounders did not substantially
change the results and the associations remained statistically
signiﬁcant.
Reverse causality is another concern, as people who have early
forms of cancer may use opium to alleviate their pain. To address
this concern, we conducted a sensitivity analyses by reassigning
cancer cases who initiated opium use within 1 year prior to
diagnosis as nonusers. With this reclassiﬁcation, the odds ratios
were reduced but were still statistically signiﬁcant. After
reclassifying the cases who started opium use 2 or 3 years prior
to diagnosis, the results were no longer statistically signiﬁcant but
the odds ratios remained much >1 and close to the original
values. However, the rate of early diagnosis of pancreas cancer is
very low [38] and by the time a person has symptoms, the cancer is
in its late stages and tumor is signiﬁcantly large. On the other
hand, pancreatic cancer is a fast-progressing cancer, after it
becomes detectable, [39] and rarely produces symptoms several
years prior to cancer, so we believe that excluding cases who only
used opium 1 or 2 years prior to diagnosis is acceptable
timeframe to address the concern of reverse causality.
Other issues of concern are biases that may arise from a case-
control design, including recall bias and selection bias. Recall
bias is unlikely, as there is little literature on opium and
pancreatic cancer to bias the opinion of the cases. More
importantly, cases and controls reported their opium use prior
to the diagnosis. Therefore, their answers could have not been
[30]
Table 4
Alcohol use in pancreatic cancer cases and controls.
Cases Controls Unadjusted OR (95%CI) for PC Adjusted
∗
OR (95%CI) for PC
N 357 328
Alcohol use, N (%)
Never used 318 (89.1) 320 (97.6) Reference Reference
Ever used 39 (10.9) 8 (2.4) 5.33 (2.46–11.54) 4.16 (1.86–9.31)
Duration
Never used 318 (89.1) 320 (97.6) Reference Reference
Median† (30 y) 18 (5.1) 4 (1.2) 4.81 (1.61–14.29) 3.49 (1.13–10.78)
>Median 21 (5.8) 4 (1.2) 5.56 (1.89–16.34) 4.11 (1.35–12.44)
Amount per month
Never used 318 (89.1) 320 (97.6) Reference Reference
Median (2.56 L) 26 (7.3) 5 (1.5) 5.23 (1.98–13.79) 4.46 (1.65–12.05)
>Median 13 (3.6) 3 (0.9) 4.36 (1.23–15.44) 2.71 (0.72–10.08)
Cumulative use‡ (duration  amount)
Never used 318 (89.1) 320 (97.6) Reference Reference
Median (47.18 L) 22 (6.2) 4 (1.2) 5.53 (1.88–16.24) 4.51 (1.5–13.51)
>Median 17 (4.8) 4 (1.2) 4.27 (1.42–12.85) 3.08 (0.98–9.67)
Age started
Never used 318 (89.1) 320 (97.6) Reference Reference
>Median 17 (4.8) 4 (1.2) 4.27 (1.42–12.85) 3.27 (1.05–10.18)
Median (21 y) 22 (6.2) 4 (1.2) 5.53 (1.88–16.24) 4.32 (1.43–13.03)
CI= conﬁdence interval, OR=odds ratio.
∗
Adjusted for age, sex, residence, opium use, and ever use of any type of tobacco.
†We used the median in control subjects as the dividing cut point.
‡ Cumulative use was calculated by multiplying amount of use (per year) by duration of use (in years).
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accentuate or reduce the odds ratios. For comparability, controls
were selected from among those who were referred for EUS,
which included patients with common bile duct stones. If such
control subjects used opium to alleviate pain, the results may be
biased toward null. In contrast, patients with the diagnosis of
opium-induced bile duct dilatation were excluded from the pool
of controls, which could bias the results away from null.
Prospective studies offer an advantage to avoid these potential
shortcomings.
The ﬁnding that pyrolysates of morphine, the most abundant
alkaloid of opium, shows strong mutagenic effects, and a
discovery of a new class of very strong class of mutagens in these
pyrolystaes,[25] lends support to the hypothesis that opium could
cause pancreatic cancer. However, the lack of a dose–response
association in our ﬁndings reduces the support for causality.
In our study population, after adjustment for other factors,
cigarette smoking was not associated with a higher risk of
pancreatic cancer. Whereas this ﬁnding is different from many
studies published across the world and resulting meta-
analyses,[26–28] it is consistent with many other studies of
smoking and cancer in Iran and some other Asian countries.[29,40]
The association of cigarette smoking with risk of several cancers,
including cancers of the esophagus,[5] stomach,[9] lung,[41] all
cancers combined,[14] and total mortality,[14] is far less strong
than what is seen in Western countries. The reasons for this
pattern are unclear, although this could be related to differences
in the intensity of smoking or other smoking behaviors in
Western and most Asian countries,[42,43] further investigation of
this phenomenon is worthwhile.
In this study, alcohol consumption was associated with a
substantial increase in risk of pancreatic cancer. Alcohol
consumption is a strong risk factor for pancreatitis.[44,45]
Meta-analyses have found an association between high con-
sumption, not low consumption, of alcohol with risk of5pancreatic cancer. Our study shows one of the strongest
associations found between alcohol and pancreatic cancer in the
literature. We are not sure whether this strong association is
causal due to alcohol itself, or it is a byproduct of the types of
alcohol used in Iran, or it is simply a matter of confounding.
Alcohol use is illegal in Iran, therefore, much of the alcohol used
in Iran over the past 35 years has been home-made. Due to its
illegal nature, there is no overseeing of production, and
adulterants may be used. Whereas we have adjusted for several
factors, residual confounding is still possible, as alcohol
consumers in Iran may be different from the rest of the
population in ways that we cannot exactly pinpoint.
This study has some strengths and limitations. This article
reports the ﬁrst epidemiologic study of opium use in relation to
pancreatic cancer. Relatively large sample size, detailed questions
on opium use and potential confounders, uniform data
collection, selecting cases and controls from the same clinics,
questioning the patients for opium use prior to diagnosis, and a
strict case and control selection criteria are also among the
strengths. The main limitation is that of most case-control studies
of cancer, that is, a potential for selection bias.
In conclusion, this study suggests that opium use and alcohol
consumption may be risk factors for pancreatic cancer in Iran.
The results for opium use are consistent with previous literature
showing that opium is associated with a host of other cancers.
Further studies, particularly prospective studies, may shed further
light on this association.References
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